carbamates has been researched along with HIV in 40 studies
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "STRATEGY-PI is a 96 week, international, multicentre, randomised, open-label, phase 3b trial in which HIV-infected adults with a plasma HIV-1 RNA viral load of less than 50 copies per mL for at least 6 months who were taking a ritonavir-boosted protease inhibitor with emtricitabine plus tenofovir were randomly assigned (2:1) either to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue on their existing regimen." | 9.19 | Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o ( Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a safe and efficacious switch option for virologically suppressed patients with HIV who have neuropsychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a multitablet NNRTI-containing regimen and want a regimen simplification." | 9.19 | Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r ( Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K, 2014) |
| "Steady-state pharmacokinetics in pregnant women prescribed ritonavir-boosted fosamprenavir (FPV) to prevent HIV transmission were assessed in the second trimester, third trimester, and postpartum." | 9.17 | Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. ( Aberg, JA; Castor, D; Cespedes, MS; Ford, SL; Lee, D; Lou, Y; Pakes, GE, 2013) |
| "The aim of this study was to compare amprenavir pharmacokinetics in HIV/hepatitis C virus (HCV)-co-infected cirrhotic patients receiving non-boosted fosamprenavir 700 mg twice daily with HCV/HIV-co-infected non-cirrhotic subjects and HIV-mono-infected subjects receiving fosamprenavir/ritonavir 700/100 mg twice daily." | 7.75 | Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ( Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M, 2009) |
| "To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir." | 7.72 | HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. ( Chou, S; Marousek, GI; Murphy, MD, 2004) |
| "STRATEGY-PI is a 96 week, international, multicentre, randomised, open-label, phase 3b trial in which HIV-infected adults with a plasma HIV-1 RNA viral load of less than 50 copies per mL for at least 6 months who were taking a ritonavir-boosted protease inhibitor with emtricitabine plus tenofovir were randomly assigned (2:1) either to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue on their existing regimen." | 5.19 | Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o ( Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a safe and efficacious switch option for virologically suppressed patients with HIV who have neuropsychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a multitablet NNRTI-containing regimen and want a regimen simplification." | 5.19 | Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r ( Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K, 2014) |
| "Steady-state pharmacokinetics in pregnant women prescribed ritonavir-boosted fosamprenavir (FPV) to prevent HIV transmission were assessed in the second trimester, third trimester, and postpartum." | 5.17 | Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. ( Aberg, JA; Castor, D; Cespedes, MS; Ford, SL; Lee, D; Lou, Y; Pakes, GE, 2013) |
| "To evaluate the pharmacokinetic compatibility of a ritonavir-boosted indinavir-fosamprenavir combination among patients with human immunodeficiency virus (HIV)." | 5.13 | Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. ( Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y, 2008) |
| "Darunavir is the result of wide and in-depth investigation into HIV protease inhibitors (PIs)." | 4.84 | [Chemical characteristics, mechanism of action and antiviral activity of darunavir]. ( Hidalgo Tenorio, C; Pasquau Liaño, J, 2008) |
| "The current recommendation for treating hepatitis C virus (HCV) in HIV patients includes the combination of sofosbuvir (SOF) and daclatasvir (DCV)." | 4.02 | Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus. ( Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K, 2021) |
| "Fosamprenavir (FPV) efficacy in human immunodeficiency virus (HIV)-infected pediatric patients is still being evaluated in ongoing clinical trials." | 3.76 | Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. ( Briz, V; de José, MI; de Ory, SJ; González-Tomé, MI; León Leal, JA; Mellado, MJ; Moreno, D; Muñoz-Fernández, MA; Palladino, C; Policarpo, SN; Ramos, JT; Silveira, LF, 2010) |
| "The aim of this study was to compare amprenavir pharmacokinetics in HIV/hepatitis C virus (HCV)-co-infected cirrhotic patients receiving non-boosted fosamprenavir 700 mg twice daily with HCV/HIV-co-infected non-cirrhotic subjects and HIV-mono-infected subjects receiving fosamprenavir/ritonavir 700/100 mg twice daily." | 3.75 | Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ( Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M, 2009) |
| "To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir." | 3.72 | HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. ( Chou, S; Marousek, GI; Murphy, MD, 2004) |
| "Amprenavir (APV) is an HIV protease inhibitor (PI) used for the treatment of either naive or PI-experienced HIV-infected patients." | 3.72 | Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. ( Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M, 2004) |
| "The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human immunodeficiency virus (HIV) infection." | 3.71 | Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. ( Clavel, F; Damond, F; Descamps, D; Duval, X; Lamotte, C; Leport, C; Peytavin, G; Race, E; Vilde, JL, 2002) |
| " We initially introduced new structural templates, particulary nonpeptidic conformationally constrained P 2 ligands that would efficiently mimic peptide binding in the S 2 subsite of the protease and provide enhanced bioavailability to the inhibitor." | 2.44 | Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. ( Chapsal, BD; Ghosh, AK; Mitsuya, H; Weber, IT, 2008) |
| "Mollecarbamates 1-4 are a family of compounds that possess repeating o-carboxyphenethylamide units and a carbamate moiety, while the molleureas 5-8 contain tetra- and penta-repeating carboxyphenethylamide units and a urea bridge in different positions." | 1.46 | Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar. ( Aknin, M; Barrows, LR; Carmeli, S; Gauvin-Bialecki, A; Issac, M; Kashman, Y; Pond, CD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.50) | 18.2507 |
| 2000's | 23 (57.50) | 29.6817 |
| 2010's | 13 (32.50) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dehghan Manshadi, SA | 1 |
| Merat, S | 1 |
| Mohraz, M | 1 |
| Rasoolinejad, M | 1 |
| Sali, S | 1 |
| Mardani, M | 1 |
| Tabarsi, P | 1 |
| Somi, MH | 1 |
| Sedghi, R | 1 |
| Tayeri, K | 1 |
| Nikbin, M | 1 |
| Karimi, J | 1 |
| Sharifi, AH | 1 |
| Kalantari, S | 1 |
| Norouzi, A | 1 |
| Merat, D | 1 |
| Malekzadeh, Z | 1 |
| Mirminachi, B | 1 |
| Poustchi, H | 1 |
| Malekzadeh, R | 1 |
| Issac, M | 1 |
| Aknin, M | 1 |
| Gauvin-Bialecki, A | 1 |
| Pond, CD | 1 |
| Barrows, LR | 1 |
| Kashman, Y | 1 |
| Carmeli, S | 1 |
| Smolders, EJ | 1 |
| Smit, C | 1 |
| T M M de Kanter, C | 1 |
| Dofferiiof, ASM | 1 |
| Arends, JE | 1 |
| Brinkman, K | 1 |
| Rijnders, B | 1 |
| van der Valk, M | 1 |
| Reiss, P | 1 |
| Burger, DM | 1 |
| Yoshimura, Y | 1 |
| Miyata, N | 1 |
| Komatsu, H | 1 |
| Tachikawa, N | 1 |
| Sulkowski, MS | 1 |
| Wu, J | 1 |
| Huang, P | 1 |
| Fan, H | 1 |
| Tian, T | 1 |
| Xia, X | 1 |
| Fu, Z | 1 |
| Wang, Y | 1 |
| Ye, X | 1 |
| Yue, M | 1 |
| Zhang, Y | 1 |
| Fulco, PP | 1 |
| Ayala-Sims, VA | 1 |
| Schrijvers, R | 1 |
| Debyser, Z | 1 |
| Arribas, JR | 1 |
| Pialoux, G | 1 |
| Gathe, J | 1 |
| Di Perri, G | 1 |
| Reynes, J | 1 |
| Tebas, P | 1 |
| Nguyen, T | 2 |
| Ebrahimi, R | 1 |
| White, K | 2 |
| Piontkowsky, D | 2 |
| Pozniak, A | 1 |
| Markowitz, M | 1 |
| Mills, A | 1 |
| Stellbrink, HJ | 1 |
| Antela, A | 1 |
| Domingo, P | 1 |
| Girard, PM | 1 |
| Henry, K | 1 |
| Garner, W | 1 |
| Guyer, B | 1 |
| Gatti, F | 1 |
| Nasta, P | 1 |
| Loregian, A | 1 |
| Puoti, M | 1 |
| Matti, A | 1 |
| Pagni, S | 1 |
| de Requena, DG | 1 |
| Prestini, K | 1 |
| Parisi, SG | 1 |
| Bonora, S | 1 |
| Palù, G | 1 |
| Carosi, G | 1 |
| Pasquau Liaño, J | 1 |
| Hidalgo Tenorio, C | 1 |
| Palladino, C | 1 |
| Briz, V | 1 |
| Policarpo, SN | 1 |
| Silveira, LF | 1 |
| de José, MI | 1 |
| González-Tomé, MI | 1 |
| Moreno, D | 1 |
| León Leal, JA | 1 |
| Mellado, MJ | 1 |
| de Ory, SJ | 1 |
| Ramos, JT | 1 |
| Muñoz-Fernández, MA | 1 |
| Breeze, S | 1 |
| Cespedes, MS | 1 |
| Castor, D | 1 |
| Ford, SL | 1 |
| Lee, D | 1 |
| Lou, Y | 2 |
| Pakes, GE | 1 |
| Aberg, JA | 1 |
| Bogner, JR | 1 |
| Eberle, J | 1 |
| Troendle, U | 1 |
| Goebel, FD | 1 |
| Schnell, T | 1 |
| Schmidt, B | 1 |
| Moschik, G | 1 |
| Thein, C | 1 |
| Paatz, C | 1 |
| Korn, K | 1 |
| Walter, H | 1 |
| Bates, M | 1 |
| Wrin, T | 1 |
| Huang, W | 1 |
| Petropoulos, C | 1 |
| Hellmann, N | 1 |
| Murphy, MD | 1 |
| Marousek, GI | 1 |
| Chou, S | 1 |
| Hasson, H | 1 |
| Gianotti, N | 1 |
| Danise, A | 1 |
| Seminari, E | 2 |
| Boeri, E | 1 |
| Nozza, S | 1 |
| Castagna, A | 1 |
| Lazzarin, A | 1 |
| Randolph, JT | 1 |
| DeGoey, DA | 1 |
| Marcelin, AG | 1 |
| Affolabi, D | 1 |
| Lamotte, C | 2 |
| Mohand, HA | 1 |
| Delaugerre, C | 1 |
| Wirden, M | 1 |
| Voujon, D | 1 |
| Bossi, P | 1 |
| Ktorza, N | 1 |
| Bricaire, F | 1 |
| Costagliola, D | 1 |
| Katlama, C | 1 |
| Peytavin, G | 2 |
| Calvez, V | 1 |
| Taourirte, M | 1 |
| Lazrek, HB | 1 |
| Rochdi, A | 1 |
| Vasseur, JJ | 1 |
| Engels, JW | 1 |
| DeJesus, E | 1 |
| Piliero, PJ | 1 |
| Summers, K | 1 |
| Wire, MB | 1 |
| Stein, DS | 1 |
| Masterman, A | 1 |
| Min, SS | 1 |
| Shelton, MJ | 1 |
| Ghosh, AK | 1 |
| Chapsal, BD | 1 |
| Weber, IT | 1 |
| Mitsuya, H | 1 |
| Spagnuolo, V | 1 |
| Gentilini, G | 1 |
| De Bona, A | 1 |
| Galli, L | 1 |
| Uberti-Foppa, C | 1 |
| Soldarini, A | 1 |
| Dorigatti, F | 1 |
| Picchio, G | 1 |
| De Meyer, S | 1 |
| de Béthune, MP | 1 |
| Ofotokun, I | 1 |
| Acosta, EP | 1 |
| Lennox, JL | 1 |
| Pan, Y | 1 |
| Easley, KA | 1 |
| Bilello, JA | 1 |
| Drusano, GL | 1 |
| Levin, J | 1 |
| Chang, HE | 1 |
| Clotet, B | 1 |
| Martínez-Picado, J | 1 |
| Arrizabalaga, J | 1 |
| Ruiz, L | 1 |
| Duval, X | 1 |
| Race, E | 1 |
| Descamps, D | 1 |
| Damond, F | 1 |
| Clavel, F | 1 |
| Leport, C | 1 |
| Vilde, JL | 1 |
| Solignac, M | 1 |
| Gallego, O | 1 |
| Corral, A | 1 |
| de Mendoza, C | 1 |
| Soriano, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of a Fixed-Dose Combination Pill of Sofosbuvir and Daclatasvir in Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus[NCT03369327] | Phase 3 | 232 participants (Actual) | Interventional | 2017-01-01 | Completed | ||
| A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir D[NCT01475838] | Phase 3 | 438 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients[NCT03789968] | 411 participants (Actual) | Observational | 2019-09-01 | Completed | |||
| A Phase 3b Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Diso[NCT01495702] | Phase 3 | 439 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01475838)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 40 |
| PI+RTV+FTC/TDF | 32 |
(NCT01475838)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 61 |
| PI+RTV+FTC/TDF | 71 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01475838)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 93.8 |
| PI+RTV+FTC/TDF | 87.1 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01475838)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 86.9 |
| PI+RTV+FTC/TDF | 69.8 |
(NCT01495702)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 56 |
| NNRTI+FTC/TDF | 58 |
(NCT01495702)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 83 |
| NNRTI+FTC/TDF | 101 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01495702)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 93.4 |
| NNRTI+FTC/TDF | 88.1 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01495702)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 86.6 |
| NNRTI+FTC/TDF | 80.4 |
6 reviews available for carbamates and HIV
| Article | Year |
|---|---|
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug | 2008 |
Practical applications of viral fitness in clinical practice.
Topics: Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests | 2003 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; | 2004 |
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Topics: Carbamates; Darunavir; Drug Design; Drug Resistance, Viral; Furans; HIV; HIV Protease; HIV Protease | 2008 |
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; | 2008 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhi | 2001 |
6 trials available for carbamates and HIV
28 other studies available for carbamates and HIV
| Article | Year |
|---|---|
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic | 2021 |
Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar.
Topics: Animals; Carbamates; HIV; Humans; Isoquinolines; Madagascar; Microbial Sensitivity Tests; Molecular | 2017 |
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
Topics: Adult; Aged; Aged, 80 and over; Amides; Anti-Retroviral Agents; Antiviral Agents; Benzofurans; Carba | 2017 |
Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Hepacivirus; Hepatitis C, | 2018 |
The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
Topics: Amides; Benzofurans; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Hepacivirus; HIV; HIV I | 2019 |
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Coinfectio | 2019 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtric | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Inf | 2014 |
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Carbamates; Chromatography, High Pressure Liquid; Elas | 2009 |
Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count | 2010 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Bl | 2012 |
Novel HIV-1 treatment Stribild™ gains regulatory approval.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, | 2012 |
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibito | 2003 |
Viral patterns of unboosted 908 identified.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial | 2003 |
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furan | 2004 |
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therap | 2004 |
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Femal | 2004 |
Homo and heterodimers of ddI, d4T and AZT: influence of (5'-5') thiolcabonate-carbamate linkage on anti-HIV activity.
Topics: Anti-HIV Agents; Antiviral Agents; Carbamates; Didanosine; Dimerization; HIV; HIV Infections; Models | 2005 |
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
Topics: Adult; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; Hepacivirus; Hepa | 2007 |
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
Topics: Antiviral Agents; Blood Proteins; Carbamates; Clinical Trials as Topic; Furans; HIV; HIV Infections; | 1996 |
[Second chance therapy. New protease inhibitor for salvage therapy].
Topics: Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; | 2000 |
New protease drug shows early promise.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Drug Resistance, Microbial; Drug Sy | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Inf | 1995 |
[Determining resistance in HIV therapy. Careful interpretation only].
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Resistance, Microbial; Furans; HIV; HIV Infect | 2001 |
Amprenavir (Agenerase).
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans | 2000 |
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Therapy, Combination; Furan | 2002 |
[Advances in the domain of HIV].
Topics: Anti-HIV Agents; Blood; Carbamates; Cerebrospinal Fluid; Drug Resistance, Viral; Drug Therapy, Combi | 2002 |
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
Topics: Amino Acid Substitution; Anti-HIV Agents; Asparagine; Carbamates; Drug Hypersensitivity; Furans; Gen | 2002 |